The Chinese insulin market would represent more than 5 billion dollars
- Advertisement -

(News Bulletin 247) – The Lyon-based company announced positive results on Thursday for a phase 1 trial evaluating the pharmacodynamics and pharmacokinetics of a dose of BioChaperone Lispro in China.

Adocia’s insulin exhibits its virtues, its share price appreciates. The Lyon-based biotechnology company specializing in the development of treatments for diabetes and other metabolic diseases announced this Thursday positive results for a phase 1 study evaluating its insulin BioChaperone Lispro in China.

- Advertisement -

Conducted in parallel with the phase 3 studies, this phase 1 trial consisted of a trial evaluating the pharmacokinetics and pharmacodynamics (to simplify the study of the reaction between the active ingredient and the body and vice versa) of a single dose of BioChaperone Lispro in Chinese healthy volunteers.

“The main objective of this study was to evaluate the faster absorption and pharmacodynamic action of BioChaperone Lispro compared to an injection of insulin lispro”, the market-leading insulin, explained the company.

This study thus showed that BioChaperone Lispro had significantly faster pharmacokinetic and pharmacodynamic properties. “In addition, BioChaperone Lispro has confirmed its good tolerance and safety profile”, assured the company.

License agreement

“These results once again demonstrate the robustness of our technology and the advantages of our product compared to the most widely used rapid-acting insulin in the world,” said Olivier Soula, Deputy CEO of Adocia, quoted in a press release. .

Remember that BioChaperone Lispro is an insulin obtained by combining Adocia’s BioChaperone technology with insulin lispro, to which it was therefore compared in this phase 1 study.

Adocia’s insulin in China has been the subject of a license agreement since 2018 with the local company Tonghua Dongbao Pharmaceutical, listed on the Shanghai Stock Exchange. This agreement enabled Adocia to receive two first payments totaling $15 million.

A vast Chinese market

BioChaperone Lispro is currently being evaluated in a Phase 3 program, which consists of two studies involving people with type 1 and type 2 diabetes at more than 100 clinical centers across China and will include a total of approximately 1,300 patients.

The results of this program will then be submitted to the Chinese regulatory authorities by Tonghua Dongbao – which is funding this program – in order to obtain marketing authorization.

In 2021, the Chinese insulin market was worth more than $5 billion, according to China Industry data cited by Adocia.

On the Paris Stock Exchange, Adocia shares appreciated the announcement and rose 9.7% around 2:05 p.m.